The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis

References

• Havasi A, Stern L, Lo S, et al. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016;91(10):E458–E460.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney. Kidney Int. 2002;61(1):1–9.
   PubMed Web of Science ®Google Scholar
• Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11–22.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240–2249.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. JCO. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85–93.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10):3960–3963.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006;1(6):1331–1341.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–2119.
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Dispenzieri A, Gertz MA, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90(3):181–186.
   PubMed Web of Science ®Google Scholar
• Basset M, Milani P, Russo F, et al. Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. Amyloid. 2017;24(sup1):60–61.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Leung N, Lacy MQ, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009;24(10):3132–3137.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–3079.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Kostopoulos IV, Terpos E, et al. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018;8(5):46.
   PubMedGoogle Scholar
• Palladini G, Massa M, Basset M, et al. Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response. Blood. 2016;128(22):3261.
   Web of Science ®Google Scholar
• Yamazaki O, Ubara Y, Suwabe T, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. Clin Exp Nephrol. 2009;13(5):522–525.
   PubMed Web of Science ®Google Scholar
• Zeier M, Perz J, Linke RP, et al. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant. 2003;18(12):2644–2647.
   PubMed Web of Science ®Google Scholar
• Safadi S, Saad A, Quint PS, et al. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis. Nephrol Dial Transplant. 2015;30(7):1151–1155.
   PubMed Web of Science ®Google Scholar
• Okuyama H, Yamaya H, Fukusima T, et al. A patient with persistent renal AL amyloid deposition after clinical remission by HDM/SCT therapy. Clin Nephrol. 2013;79(3):233–236.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med. 1982;142(8):1445–1447.
   PubMedGoogle Scholar
• Roth RM, Benson D, Hebert LA, et al. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis. Arch Pathol Lab Med. 2013;137(9):1304–1308.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Richardson S, MacSweeney JE, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med. 1993;86(6):365–374.
   PubMedGoogle Scholar
• Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508–513.
   PubMed Web of Science ®Google Scholar
• Lee H, Duggan P, Neri P, et al. Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? Bone Marrow Transplant. 2017;52(6):915–917.
   PubMed Web of Science ®Google Scholar
• Milani P, Murray DL, Barnidge DR, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92(8):772–779.
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–596.
   PubMed Web of Science ®Google Scholar
• van G II, Bijzet J, Bos R, et al. Measurable regression of systemic light chain (AL) amyloid in fat tissue after a response of amyloidogenic free light chain in serum. Amyloid. 2011;18(Suppl 1):94–95.
   PubMedGoogle Scholar
• Menn-Josephy H, Lee CS, Nolin A, et al. Renal interstitial fibrosis: an imperfect predictor of kidney disease progression in some patient cohorts. Am J Nephrol. 2016;44(4):289–299.
   PubMed Web of Science ®Google Scholar
• Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008–1010.
   PubMed Web of Science ®Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854–3858.
   PubMed Web of Science ®Google Scholar
• Soares SM, Fervenza FC, Lager DJ, et al. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am J Kidney Dis. 2008;52(6):1079–1083.
   PubMed Web of Science ®Google Scholar